The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Modulation of endothelial cell hemostatic properties by tumor necrosis factor.
Nawroth, P. P., & Stern, D. M. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.3.740 · Cited by 1,311
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R., Shapiro, L., Arap, W., & Ruoslahti, E. I. (2000) · PubMed · Cited by 966
αv Integrins as receptors for tumor targeting by circulating ligands
Pasqualini, R., Koivunen, E., & Ruoslahti, E. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-542 · Cited by 744
Ljunggren, H. G., & Kärre, K. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.6.1745 · Cited by 736
Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., & Lejeune, F. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.52 · Cited by 719
Tumor targeting with a selective gelatinase inhibitor
Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O. P., Heikkilä, P., Kantor, C., Gahmberg, C. G., Salo, T., Konttinen, Y. T., et al. (1999) · Nature Biotechnology · doi:10.1038/11703 · Cited by 567
Aminopeptidases: structure and function
Taylor, A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.2.8440407 · Cited by 554
Eggermont, A. M. M., Koops, H. S., Klausner, J. M., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., et al. (1996) · Annals of Surgery · doi:10.1097/00000658-199612000-00011 · Cited by 460
Cited by
Specialization of tumour vasculature
Ruoslahti, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc724 · Cited by 722
Gelatinase-mediated migration and invasion of cancer cells
Björklund, M., & Koivunen, E. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.03.001 · Cited by 661
Steps toward mapping the human vasculature by phage display
Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardó-Vila, M., Giordano, R. J., Mintz, P. J., Ardelt, P. U., Yao, V. J., Vidal, C. I., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-121 · Cited by 607
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Müller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A., & Trepel, M. (2003) · Nature Biotechnology · doi:10.1038/nbt856 · Cited by 410
The moonlighting enzyme CD13: old and new functions to target
Mina-Osorio, P. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.06.003 · Cited by 405
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Aminopeptidase N (CD13) as a target for cancer chemotherapy
Wickström, M., Larsson, R., Nygren, P., & Gullbo, J. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2010.01826.x · Cited by 358
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Therapeutic cancer targeting peptides
Aina, O. H., Sroka, T. C., Chen, M., & Lam, K. S. (2002) · Peptide Science · doi:10.1002/bip.10257 · Cited by 308
The TNF Paradox in Cancer Progression and Immunotherapy
Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., & Ségui, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01818 · Cited by 305
Porkka, K., Laakkonen, P., Hoffman, J. A., Bernasconi, M., & Ruoslahti, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062189599 · Cited by 291
Targeting the prostate for destruction through a vascular address
Arap, W., Haedicke, W., Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H. M., Bredesen, D. E., Pasqualini, R., & Ruoslahti, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241655998 · Cited by 285
Apoptosis-based therapies and drug targets
Fischer, U., & Schulze-Osthoff, K. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401556 · Cited by 282
Display technologies: Application for the discovery of drug and gene delivery agents☆
SERGEEVA, A., KOLONIN, M., MOLLDREM, J., PASQUALINI, R., & ARAP, W. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.018 · Cited by 266
New Approaches and Therapeutics Targeting Apoptosis in Disease
Fischer, U., & Schulze-Osthoff, K. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.6 · Cited by 257
Lien, S., & Lowman, H. B. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.10.005 · Cited by 209
Tumor target amplification: Implications for nano drug delivery systems
Seidi, K., Neubauer, H. A., Moriggl, R., Jahanban-Esfahlan, R., & Javaheri, T. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.020 · Cited by 145
Metadata
- Authors
- Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A.
- Venue
- Nature Biotechnology
- Published
- 2000-11
- Volume
- 18
- Issue
- 11
- Pages
- 1185-1190
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1559937222
- Cited by
- 419
- References
- 26
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.